Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2005-000693-45-IT
EUCTR2005-000693-45-IT
Active, Not Recruiting
N/A

A phase II study for the treatment of patients with splenic marginal lymphoma with the combination of Cyclophosfamide, Vincristine, Liposomal Doxorubicin, Predinisone and Rituximab

G.I.S.L. - GRUPPO ITALIANO STUDIO LINFOMI0 sitesApril 6, 2007
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsTreatment of patients with newly diagnosed splenic marginal non Hodgkin lymphomaMedDRA version: 9.1Level: LLTClassification code 10062113Term: Splenic marginal zone lymphoma
DrugsMABTHERA EV 1FL 50ML 500MGENDOXAN BAXTER EV 1FL 500MGVINCRISTINA PHARMACIA U. 2MGMYOCET INFUS 2SET 50MGDELTACORTENE FORTE 10CPR 25MG

Overview

Phase
N/A
Intervention
Not specified
Conditions
Treatment of patients with newly diagnosed splenic marginal non Hodgkin lymphoma
Sponsor
G.I.S.L. - GRUPPO ITALIANO STUDIO LINFOMI
Status
Active, Not Recruiting
Last Updated
14 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 6, 2007
End Date
TBD
Last Updated
14 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
G.I.S.L. - GRUPPO ITALIANO STUDIO LINFOMI

Eligibility Criteria

Inclusion Criteria

  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range
  • •F.1\.3 Elderly (\>\=65 years) yes
  • •F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, Not Recruiting
N/A
A phase II study of management of the patients with locally advanced (FIGO III & IVa or stage II unfavorably located lesion) or relapsed vulvar carcinomaocally advanced (FIGO III & IVa or stage II unfavorably located lesion) or relapsed vulvar carcinoma.
EUCTR2004-005218-35-SEordic Society of Gynecological Oncology (NSGO)50
Active, Not Recruiting
Phase 1
Study to assess the value of a nuclear medicine procedure (Tc-99m tetrofosmin SPECT) to identify tumor recurrence in patients with brain tumors after radiation therapy.Patients with high grade brain tumorsMedDRA version: 20.0Level: PTClassification code 10065443Term: Malignant gliomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2015-005573-21-HUpro-ACTINA S.A.51
Active, Not Recruiting
Phase 1
Study to assess the value of a nuclear medicine procedure (Tc-99m tetrofosmin SPECT) to identify tumor recurrence in patients with brain tumors after radiation therapy.Patients with high grade brain tumorsMedDRA version: 20.0Level: PTClassification code 10065443Term: Malignant gliomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2015-005573-21-FRpro-ACTINA S.A.30
Active, Not Recruiting
Phase 1
Study to assess the value of a nuclear medicine procedure (Tc-99m tetrofosmin SPECT) to identify tumor recurrence in patients with brain tumors after radiation therapy.Patients with high grade brain tumorsMedDRA version: 18.1Level: PTClassification code 10065443Term: Malignant gliomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2015-005573-21-DEpro-ACTINA S.A.30
Active, Not Recruiting
N/A
A Phase 2B Pilot Study of Short-Term Treatment of BMS-790052 in Combination with Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects with Chronic Hepatitis C Genotype 2 or 3 Infection. - ND
EUCTR2010-022408-28-ITBristol-Myers Squibb International Corporation210